This is the first in a series of LillyPad blog posts on the emerging pandemic. It is intended to provide information about what Lilly and other pharmaceutical companies are doing to contribute to the fight in Canada and worldwide.
Lilly is confronting this pandemic with everything we can. We’ve redirected scientific efforts to help solve critical issues – including potential therapeutics, diagnostics and testing.
We are moving at top speed to create a potential treatment.
Lilly has joined efforts with AbCellera to co-develop antibodies for the potential treatment and prevention of COVID-19. The collaboration will leverage AbCellera's rapid pandemic response platform and Lilly's global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies.
We’re energized as the biopharmaceutical industry has galvanized to defeat the virus, mustering resources with other partners to find solutions to the pandemic’s most urgent issues.
Lilly is willing to work with all interested collaborators – government, academia, other companies – to share data and expertise to defeat this threat.
We join industry partners in directing discretionary resources to find a treatment or vaccine as quickly as possible -- and deploy our expert workforce, including medical professionals and scientists, to help fight the virus on the front lines.
Responding urgently to global crisis is a hallmark of Lilly’s history.
Lilly partnered with the American Red Cross during both World Wars -- setting up a medical field hospital in France (staffed by Indiana personnel) to treat wounded soldiers of all nationalities during WWI, and processing blood plasma for the Red Cross during World War II. Lilly was among the first companies during the Second World War to develop a method to mass-produce Penicillin-G, the world’s first widely available antibiotic.
In the 1950s, we quickly ramped up production to become the first company to manufacture and distribute the Salk Polio Vaccine globally.
Lilly is proud to contribute to the fight against COVID-19.